Targets › TCF4
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Mar 2029.
Transcription factor that binds to the immunoglobulin enhancer Mu-E5/KE5-motif. Involved in the initiation of neuronal differentiation. (UniProt, P15884)
Open in Phaseline: the race on TCF4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mahzi Therapeutics | MZ-1866 AAV-9 gene therapy for TCF4 gene replacement | TCF4 | Phase 1 | Pitt Hopkins Syndrome | Mar 2029 |
Pitt Hopkins Syndrome (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.